Genome editing and chimeric antigen receptors t cell therapy

Abstract EN

Recent advances in genome editing technologies have significantly enhanced making specific changes in the genomes of different types cells.

Genetically engineered T cells, or the 'living drugs', is considered a new era in antitumor therapy.

Current clinical trials using chimeric antigen receptors (CARs) T cells showed a promising result in patients with some intractable hematological malignancies.

In this Review, some of the most recent advances in CAR T cell therapy are mentioned high lightening the use of genome editing in this field.